Kevin Dennis  Green net worth and biography

Kevin Green Biography and Net Worth

CFO of Cerus

Mr. Green was appointed our Chief Financial Officer in 2013. From 2006 to 2013, Mr. Green served in several roles for us including Senior Director of Finance, Controller and most recently, Vice President, Finance and Chief Accounting Officer. From 2000 until 2006, Mr. Green held various financial management positions with Macromedia, Inc., a software company acquired by Adobe Systems in 2005, including Director of Finance and Assistant Controller. Prior to joining Macromedia, Mr. Green was a member of PricewaterhouseCoopers LLP in the Assurance and Business Advisory Services division.

Mr. Green is a certified public accountant (inactive).

What is Kevin Dennis Green's net worth?

The estimated net worth of Kevin Dennis Green is at least $1.02 million as of September 3rd, 2024. Mr. Green owns 590,365 shares of Cerus stock worth more than $1,015,428 as of November 17th. This net worth evaluation does not reflect any other investments that Mr. Green may own. Additionally, Mr. Green receives a salary of $607,530.00 as CFO at Cerus. Learn More about Kevin Dennis Green's net worth.

How old is Kevin Dennis Green?

Mr. Green is currently 52 years old. There are 4 older executives and no younger executives at Cerus. The oldest executive at Cerus is Dr. Laurence M. Corash M.D., Co-Founder & Chief Scientific Officer, who is 80 years old. Learn More on Kevin Dennis Green's age.

What is Kevin Dennis Green's salary?

As the CFO of Cerus Co., Mr. Green earns $607,530.00 per year. There are 3 executives that earn more than Mr. Green. The highest earning executive at Cerus is Mr. William M. Greenman, President, CEO & Director, who commands a salary of $1,040,000.00 per year. Learn More on Kevin Dennis Green's salary.

How do I contact Kevin Dennis Green?

The corporate mailing address for Mr. Green and other Cerus executives is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. Cerus can also be reached via phone at (925) 288-6000 and via email at [email protected]. Learn More on Kevin Dennis Green's contact information.

Has Kevin Dennis Green been buying or selling shares of Cerus?

Kevin Dennis Green has not been actively trading shares of Cerus within the last three months. Most recently, Kevin Dennis Green sold 28,385 shares of the business's stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $2.18, for a transaction totalling $61,879.30. Following the completion of the sale, the chief financial officer now directly owns 590,365 shares of the company's stock, valued at $1,286,995.70. Learn More on Kevin Dennis Green's trading history.

Who are Cerus' active insiders?

Cerus' insider roster includes Laurence Corash (Insider), Kevin Green (CFO), William Greenman (CEO), Vivek Jayaraman (COO), Chrystal Menard (Insider), Carol Moore (SVP), Gail Schulze (Director), and Daniel Swisher, Jr. (Director). Learn More on Cerus' active insiders.

Are insiders buying or selling shares of Cerus?

In the last year, Cerus insiders bought shares 3 times. They purchased a total of 15,000 shares worth more than $25,875.00. In the last year, insiders at the biotechnology company sold shares 8 times. They sold a total of 227,506 shares worth more than $488,803.79. The most recent insider tranaction occured on September, 3rd when CFO Kevin Dennis Green sold 28,385 shares worth more than $61,879.30. Insiders at Cerus own 3.4% of the company. Learn More about insider trades at Cerus.

Information on this page was last updated on 9/3/2024.

Kevin Dennis Green Insider Trading History at Cerus

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/3/2024Sell28,385$2.18$61,879.30590,365View SEC Filing Icon  
3/14/2024Sell21,497$1.97$42,349.09618,750View SEC Filing Icon  
3/13/2023Sell17,163$2.80$48,056.40421,797View SEC Filing Icon  
5/10/2022Sell57,335$4.98$285,528.30222,999View SEC Filing Icon  
3/14/2022Sell32,102$5.04$161,794.08View SEC Filing Icon  
11/3/2021Sell95,741$7.00$670,187.00View SEC Filing Icon  
11/10/2020Sell32,928$5.49$180,774.72130,253View SEC Filing Icon  
8/10/2020Sell68,585$6.96$477,351.60200,981View SEC Filing Icon  
3/17/2020Sell26,625$3.59$95,583.7586,773View SEC Filing Icon  
4/10/2019Sell2,786$6.51$18,136.8682,059View SEC Filing Icon  
3/12/2019Sell23,524$2.05$48,224.2066,825View SEC Filing Icon  
2/11/2019Sell2,783$5.86$16,308.3863,608View SEC Filing Icon  
1/10/2019Sell2,783$5.59$15,556.9763,608View SEC Filing Icon  
12/10/2018Sell2,783$5.35$14,889.0563,608View SEC Filing Icon  
11/12/2018Sell2,783$5.56$15,473.4863,608View SEC Filing Icon  
10/10/2018Sell2,783$6.09$16,948.4763,608View SEC Filing Icon  
9/10/2018Sell2,783$7.24$20,148.9263,608View SEC Filing Icon  
8/28/2018Sell50,000$7.50$375,000.00110,825View SEC Filing Icon  
8/10/2018Sell2,783$6.96$19,369.6860,875View SEC Filing Icon  
5/17/2018Sell73,000$6.42$468,660.0083,825View SEC Filing Icon  
3/12/2018Sell2,063$4.80$9,902.4058,062View SEC Filing Icon  
3/15/2017Sell2,343$4.21$9,864.03View SEC Filing Icon  
8/22/2016Sell17,150$6.80$116,620.00View SEC Filing Icon  
See Full Table

Kevin Dennis Green Buying and Selling Activity at Cerus

This chart shows Kevin Dennis Green's buying and selling at Cerus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cerus Company Overview

Cerus logo
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
Read More

Today's Range

Now: $1.72
Low: $1.69
High: $1.82

50 Day Range

MA: $1.78
Low: $1.52
High: $2.07

2 Week Range

Now: $1.72
Low: $1.38
High: $2.59

Volume

1,496,205 shs

Average Volume

2,012,547 shs

Market Capitalization

$319.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2